Prestige Consumer Healthcare (NYSE:PBH) Upgraded at Raymond James

Raymond James upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) to a moderate buy rating in a report published on Thursday,Zacks.com reports.

Other research analysts have also issued reports about the stock. DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $78.72 on Thursday. The firm has a market cap of $3.89 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 2.32 and a beta of 0.49. The firm has a fifty day moving average price of $79.25 and a 200 day moving average price of $73.10. Prestige Consumer Healthcare has a fifty-two week low of $57.95 and a fifty-two week high of $86.36. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. The business had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.07 EPS. As a group, sell-side analysts expect that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. This represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 in the last quarter. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Martingale Asset Management L P raised its stake in shares of Prestige Consumer Healthcare by 0.4% in the 3rd quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock valued at $2,666,000 after acquiring an additional 140 shares during the period. Horizon Kinetics Asset Management LLC raised its position in Prestige Consumer Healthcare by 4.8% in the third quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company’s stock valued at $234,000 after purchasing an additional 150 shares during the period. Evergreen Capital Management LLC lifted its stake in Prestige Consumer Healthcare by 5.4% during the second quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock worth $216,000 after purchasing an additional 160 shares in the last quarter. Miller Howard Investments Inc. NY boosted its position in shares of Prestige Consumer Healthcare by 2.2% during the second quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock worth $534,000 after buying an additional 165 shares during the period. Finally, OLD National Bancorp IN grew its stake in shares of Prestige Consumer Healthcare by 4.4% in the third quarter. OLD National Bancorp IN now owns 3,974 shares of the company’s stock valued at $287,000 after buying an additional 168 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.